Program
Isosorbide
Also written as “Isosorbide oral solution”, “AT101(Anti-CD19 Chimeric Antigen Receptor T cell)” and “Isobide”.
Its studies are mostly in Hearing Loss · Lymphoma, B-Cell · Meniere Disease, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbClon | 11 open or running | phase 2since Apr 1, 2022 | Apr 1, 2022 | Mar 15, 2030phase 2 · NCT05338931 |
| Lotus Pharmaceutical | 10 open or running | phase 4since Mar 21, 2016 | Mar 21, 2016 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 3since Dec 23, 2024 | Dec 23, 2024 | Jun 30, 2027phase 3 · NCT06765993 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 21, 2016First study: phase 4 study in Meniere DiseaseNew to Lotus PharmaceuticalLotus Pharmaceutical · NCT02718846 · 220 enrolled
- Apr 1, 2022AbClon's first study: phase 2 study in Lymphoma, B-CellNew to AbClonAbClon · NCT05338931 · 82 planned · Korea, Republic of
- Dec 23, 2024Lunan Pharmaceutical Group's first study: phase 3 study in Hearing LossNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06765993 · 234 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Hearing LossLunan Pharmaceutical Group · NCT06765993
- Mar 15, 2030Primary completion: phase 2 study in Lymphoma, B-CellAbClon · NCT05338931
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06765993Hearing Loss | 3 | Not yet recruiting | Lunan Pharmaceutical Group | Jun 30, 2027 | 234 |
| NCT05338931Lymphoma, B-Cell · Korea, Republic of | 2 | Recruiting | AbClon | Mar 15, 2030 | 82 |
| NCT02718846Meniere Disease | 4 | Completed | Lotus Pharmaceutical | May 2015 | 220 |
How it is read
Names in the registry
- “Isosorbide oral solution”, 1 entry
- “AT101(Anti-CD19 Chimeric Antigen Receptor T cell)”, 1 entry
- “Isobide”, 1 entry
Conditions, from the studies’ own filings
- Hearing Loss, 1 study
- Lymphoma, B-Cell, 1 study
- Meniere Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.